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Introduction
The prevalence of epilepsy is approximately 0.5–1.0% and about 70% of patients 
will become seizure-free from first–line anti-epileptic drugs (1-4). 
Refractory seizures are associated with cognitive and behavioral problems and 
impaired psychosocial development (5-7).
There are many effective drugs effective for epilepsy, some of which are the main 
Abstract
Objective 
The prevalence of active epilepsy is about 0.5–1%, and approximately 70% of 
patients are cured with first anti-epileptic drugs and the remaining patients need 
multiple drugs. Pregabalin as an add-on therapy has a postive effect on refractory 
seizures in adults. To the best of our knowledge, there is no research with this 
drug in childhood epilepsy. We use pregabalin in children with refractory seizures 
as an add-on therapy. The objective of this study is to evaluate the effects of 
pregabalin in the reduction of seizures for refractory epilepsy.
Material & Methods
Forty patients with refractory seizures who were referred to Mofid Children’s 
Hospital and Hazrat Masoumeh Hospital were selected. A questionnaire based 
on patient record forms, demographic data (age, gender,…), type of seizure, 
clinical signs, EEG record, imaging report, drugs that had been used, drugs 
currently being used, and the number of seizures before and after Pregabalin 
treatment was completed. We checked the number of seizures after one and four 
months.
Results
After one month, 26.8% of patients had more than a 50% reduction in seizures 
and 14.6% of these patients were seizure-free; 12.2% had a 25–50% reduction; 
and approximately 61% had less than a 25% reduction or no change in seizures.
After the fourth month, 34.1% of patients had more than a 50% reduction in 
seizures and 24.4% of these patients were seizure-free. Additionally, 65.9% of 
patients had less than 50% reduction in seizures (9.8% between 25–50% and 
56.1% less than 25% or without improvement).
Conclusion
We recommend Pregabalin as an add-on therapy for refractory seizures (except 
for myoclonic seizures) for children.
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were referred to Mofid Children’s Hospital and Hazrat 
Masomeh Hospital.
A questionnaire based on the patient record form, 
demographic data (age, gender, among others), type of 
seizure, clinical signs, electroencephalography (EEG) 
record, imaging report, drugs that had been used, drugs 
currently being used, and the numbers of seizures before 
and after pregabalin treatment were recorded.
Pregabalin of 5–15 mg/kg/day were prescribed. 
Follow-up on these patients was done for 4 months. 
Patients were visited after one month, and numbers of 
seizures were recorded and the patients were divided 
into 100%, 75–100%, 50–75%, <50%, and without 
response groups.
This study was registered as an Iranian clinical trials 
with registration number IRCT2014012216320N1 code.
 
Results
The mean age of the patients was 74.46 ± 4.39 months 
(range 11–168 months). The first seizure was in 19.5 ± 
2.4 Months. The mean duration of seizure was 51 ± 35 
months (range 1–138 months). Fifteen (36.6%) patients 
were female and 25 (63.4%) were male (Table 1). The 
types of seizure were as follows: 22% tonic clonic, 22% 
complex partial seizure (CPS), and 56% mixed type 
seizure.
drugs and some are adjunctive drugs for treatment.
Pregabalin is an adjunctive drug and an alpha-2-delta 
ligand with anxiolytic, analgesic, and antiepileptic 
activity.
Pregabalin binds to the alpha-2-delta protein, which is an 
auxiliary protein associated with voltage-gated calcium 
channels; thereby, decreasing calcium influx at nerve 
terminals and, subsequently, the release of excitatory 
neurotransmitter glutamate.
Pregabalin has no efficacy at GABAa and GABAb 
receptors (8,9). 
Pregabalin has a pharmacological effect similar to 
GABApentin, but with a 3- to 10-fold increased potency 
(10).
There are many studies indicating that pregabalin is 
highly effective as an add-on therapy in adult patients 
with partial seizures, with or without secondary 
generalization (11-14).
There is little research concerning the effect of Pregabalin 
on childhood intractable epilepsy (15). 
Pregabalin has a few side effects of which dizziness and 
somnolence are the most common (16).
Materials & Methods
In this interventional research, we prescribed Pregabalin 
as an add-on therapy to children with refractory seizures. 
We selected 40 patients with refractory seizures who 
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Table 1. The mean and standard deviation of age, duration of seizure, and age of first seizure
Variable Mean Standard deviation Minimum Maximum
Age (months) 74.46 4.39 11 168
Duration (months) 51 35 1 138
Age of first seizure (months) 19.5 24.2 1 120
An EEG was done for all patients, and 17.1% of patients 
had a normal EEG and the remainder had abnormal 
EEGs. All of these patients had neuroimaging and 53.7% 
showed normal results.
Eight patients had more seizures before treatment with 
Pregabalin (4 per day).
After one month, 26.8% had more than a 50% reduction 
in seizures and 14.6% of these patients were seizure-
free; 12.2% had between 25–50% reduction; and about 
61% had less than 25% or no change in seizures.
After four months, 34.1% of patients had more than a 
50% reduction in seizures and 24.4% were seizure-free. 
Additionally, 65.9% had less than a 50% reduction in 
their seizures (9.8% between 25–50% and 56.1% less 
than 25% or without improvement).
The mean rate of seizures before intervention was 
13.17%, but this rate was 9.97% and 9.39%, one month 
and four month after pregabalin, respectively.
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About 9.7% of patients had side-effects with headache 




Pregabalin has been licensed as an antiepileptic drug for 
adjunctive therapy in adults with partial seizures with 
and without secondary generalization.
Carreno et al. reported a 52% reduction of more than 
50% in seizures with Pregabalin as an add-on therapy 
in adults with refractory partial seizures. Additionally, 
he reported a 60% adverse effect of which weight gain 
was the most frequent (14). In our research, all types 
of refractory seizures (partial and generalized) were 
experienced in childhood and we reduced seizures by 
about 34.1%. 
Gil-Nagel et al. in a pooled data analysis of four 
randomized placebo-controlled trials confirmed the 
Table 2. Mean Rate of Seizures Before and After Intervention with Pregabalin
                                                               Mean               S.D
Before intervention                              13.17               5.59
One month after intervention             9.97                6.18
Four month after intervention            9.39                7.07
The results of ANOVA with repetitive measurements show a significant difference between the mean rate of seizures 









fects at all. 
 








t common (2.4%) and about 
Fig 1. Effect of pregab lin on reduction of seizure
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effect of Pregabalin in refractory partial seizures in 
adults, but more frequent side-effects were dizziness and 
somnolence, which is compatible with our findings (17).
Jan et al. prescribed Pregabalin as add-on therapy in 19 
children with refractory epilepsy and reported that 6% of 
children became seizure-free and 37% had more than a 
50% reduction in seizures (15). The sample size of this 
research was small but the results were similar to our 
study. He prescribed Pregabalin 150–300 mg/day, but in 
our study, the drug was started with 2 mg/kg and then 
was increased to 10 mg/kg.
There is no clear-cut evidence regarding the effective 
level and the toxic level of Pregabalin in children. 
A total of 34.1% of patients had more than a 50% 
reduction in seizure frequency after four months of 
treatment. 
However, more trials with a greater sample size and 
long-term use of Pregabalin are needed to judge its long-
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term effectiveness for different types of epilepsy. We 
recommend Pregabalin as add-on therapy in childhood 
refractory seizures, especially in patients with partial 
seizures and secondary generalized seizures. We suggest 
studying the pharmacokinetic of Pregabalin in childhood 
as a future study area. 
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